Comparative Proteomic Profiling of Human Bile Reveals SSP411 as a Novel Biomarker of Cholangiocarcinoma

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Shen, Jian ^a,b   Wang, Weizhi ^a   Wu, Jindao ^a   Feng, Bing ^a   Chen, Wen ^a   Wang, Meng ^a   Tang, Jincao ^a   Wang, Fuqiang ^c   Cheng, Feng ^a   Pu, Liyong ^a   Tang, Qiyun ^a   Wang, Xuehao ^a   Li, Xiangcheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHAPERONIN; PHOSPHOGLYCERATE MUTASE; PHOSPHOGLYCERATE MUTASE 1; PROTEIN DISULFIDE ISOMERASE; PROTEIN DISULFIDE ISOMERASE FAMILY A MEMBER 3; PROTEIN SSP411; SPERMATOGENESIS ASSOCIATED PROTEIN 20; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILE; BILE DUCT CARCINOMA; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CHOLANGITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

AGED; BILE; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84868267210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047476     Document Type: Article

References (46)

1. Tyson GL, El-Serag HB, (2011) Risk factors for cholangiocarcinoma. Hepatology 54: 173-184.
2. Blechacz BR, Gores GJ, (2008) Cholangiocarcinoma. Clin Liver Dis 12: 131-150, ix.
3. Nehls O, Gregor M, Klump B, (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24: 139-154.
4. Lee SG, Song GW, Hwang S, Ha TY, Moon DB, et al. (2010) Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 17: 476-489.
5. Hirano S, Kondo S, Tanaka E, Shichinohe T, Tsuchikawa T, et al. (2010) Outcome of surgical treatment of hilar cholangiocarcinoma: a special reference to postoperative morbidity and mortality. J Hepatobiliary Pancreat Sci 17: 455-462.
6. Nguyen K, Sing JT Jr, (2008) Review of endoscopic techniques in the diagnosis and management of cholangiocarcinoma. World J Gastroenterol 14: 2995-2999.
7. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr, (2001) Proteomics in early detection of cancer. Clin Chem 47: 1901-1911.
8. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, et al. (2004) A proteomic analysis of human bile. Mol Cell Proteomics 3: 715-728.
9. Farina A, Dumonceau JM, Lescuyer P, (2009) Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev Proteomics 6: 285-301.
10. Farina A, Dumonceau JM, Frossard JL, Hadengue A, Hochstrasser DF, et al. (2009) Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res 8: 159-169.
11. Zhou H, Chen B, Li RX, Sheng QH, Li SJ, et al. (2005) Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach. Rapid Commun Mass Spectrom 19: 3569-3578.
12. Chen B, Dong JQ, Chen YJ, Wang JM, Tian J, et al. (2007) Two-dimensional electrophoresis for comparative proteomic analysis of human bile. Hepatobiliary Pancreat Dis Int 6: 402-406.
13. Farina A, Dumonceau JM, Delhaye M, Frossard JL, Hadengue A, et al. (2011) A step further in the analysis of human bile proteome. J Proteome Res 10: 2047-2063.
14. Farid SG, Craven RA, Peng J, Bonney GK, Perkins DN, et al. (2011) Shotgun proteomics of human bile in hilar cholangiocarcinoma. Proteomics 11: 2134-2138.
15. Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, et al. (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875-884.
16. Huang XY, Guo XJ, Shen J, Wang YF, Chen L, et al. (2008) Construction of a proteome profile and functional analysis of the proteins involved in the initiation of mouse spermatogenesis. J Proteome Res 7: 3435-3446.
17. Wu J, Tang Q, Shen J, Yao A, Wang F, et al. (2010) Comparative proteome profile during the early period of small-for-size liver transplantation in rats revealed the protective role of Prdx5. J Hepatol 53: 73-83.
18. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, et al. (2004) The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427: 461-465.
19. Agoston AT, Argani P, Yegnasubramanian S, De Marzo AM, Ansari-Lari MA, et al. (2005) Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem 280: 18302-18310.
20. Shaib Y, El-Serag HB, (2004) The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-25 8: 4092-4103.
21. Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, et al. (2010) Cholangiocarcinoma: update and future perspectives. Dig Liver Dis 42: 253-60.
22. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR, (2009) High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 50: 158-64.
23. Burak K, Angulo P, Pasha TM, Egan K, Petz J, et al. (2004) Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99: 523-6.
24. Poomphakwaen K, Promthet S, Kamsa-Ard S, Vatanasapt P, Chaveepojnkamjorn W, et al. (2009) Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study. Asian Pac J Cancer Prev 10: 251-8.
25. Khan SA, Toledano MB, Taylor-Robinson SD, (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 10: 77-82.
26. Okuda K, Nakanuma Y, Miyazaki M, (2002) Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 17: 1049-55.
27. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, et al. (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 5: 1221-8.
28. Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, et al. (2007) Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 120: 638-641.
29. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, et al. (2004) Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 101: 1609-1615.
30. Wang X, Dai S, Zhang Z, Liu L, Wang J, et al. (2009) Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma. Eur J Cancer Care (Engl) 18: 625-635.
31. Korita PV, Wakai T, Ajioka Y, Inoue M, Takamura M, et al. (2010) Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma. Anticancer Res 30: 2279-2285.
32. Dos Santos A, Court M, Thiers V, Sar S, Guettier C, et al. (2010) Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol Cell Proteomics 9: 1991-2004.
33. Srisomsap C, Sawangareetrakul P, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, et al. (2010) Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol 2010: 437143.
34. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, et al. (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5: 4589-4596.
35. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, et al. (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34: 205-214.
36. Takaishi S, Wang TC, (2007) Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer. Cancer Sci 98: 284-293.
37. Halton JM, Nazir DJ, McQueen MJ, Barr RD, (1998) Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer 83: 379-384.
38. de Atauri P, Repiso A, Oliva B, Vives-Corrons JL, Climent F, et al. (2005) Characterization of the first described mutation of human red blood cell phosphoglycerate mutase. Biochim Biophys Acta 1740: 403-410.
39. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF, (2005) Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol 23: 1303-1307.
40. Ren F, Wu H, Lei Y, Zhang H, Liu R, et al. (2010) Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 9: 81.
41. Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, et al. (2008) Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS 116: 888-895.
42. Cappello F, David S, Rappa F, Bucchieri F, Marasa L, et al. (2005) The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 5: 139.
43. Cappello F, Conway de Macario E, Marasa L, Zummo G, Macario AJ, (2008) Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biol Ther 7: 801-809.
44. Cicchillitti L, Della Corte A, Di Michele M, Donati MB, Rotilio D, et al. (2010) Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and-resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin. Int J Oncol 37: 445-454.
45. Turano C, Gaucci E, Grillo C, Chichiarelli S, (2011) ERp57/GRP58: a protein with multiple functions. Cell Mol Biol Lett 16: 539-563.
46. Shi HJ, Wu AZ, Santos M, Feng ZM, Huang L, et al. (2004) Cloning and characterization of rat spermatid protein SSP411: a thioredoxin-like protein. J Androl 25: 479-493.